• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解血友病患者参与体育活动的最低和理想因子水平:一项专家 elicitation 研究。

Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise.

机构信息

HCD Economics, Daresbury, UK.

Faculty of Health and Social Care, University of Chester, Chester, UK.

出版信息

Haemophilia. 2020 Jul;26(4):711-717. doi: 10.1111/hae.13985. Epub 2020 Apr 8.

DOI:10.1111/hae.13985
PMID:32268007
Abstract

INTRODUCTION

The benefits of physical activity (PA) for people with haemophilia (PWH) may include improvements in joint, bone and muscle health. However, the factor VIII activity level required to avoid a bleeding episode associated with PA is unknown.

AIM

To elicit the opinion of clinical experts on the minimum level and ideal factor VIII activity ('level') required to avoid a bleeding episode during participation in different types of PA for PWH.

METHODS

Based on the 2017 National Hemophilia Foundation PA descriptions, clinical experts estimated a minimally acceptable and an ideal factor level at which a bleed could be avoided. The uncertainty around estimates was quantified using an approach to construct a probability distribution to represent expert opinion.

RESULTS

Minimum and ideal factor level increased with higher risk PA, whether or not joint morbidity was present, as did the experts' uncertainty in their estimates (ie the range between lowest and highest estimates for minimum and ideal levels). Mean minimum levels ranged from 4% to 48% for low to high risk for people without joint morbidity, and from 7% to 47% for those with joint morbidity. For ideal factor levels, corresponding figures were 9%-52% and 12%-64%, respectively.

CONCLUSION

To support a patient-centric outcome, expert opinion indicates that the clinical norm of 0.01 IU/mL (1%) trough level is insufficient. It is anticipated that introducing a more targeted approach to meet the needs of patients who are increasingly physically active will benefit patients further in addition to recent treatment advances.

摘要

简介

身体活动(PA)对血友病患者(PWH)可能有益,包括改善关节、骨骼和肌肉健康。然而,避免与 PA 相关的出血事件所需的因子 VIII 活性水平尚不清楚。

目的

征求临床专家对 PWH 参与不同类型 PA 时避免出血事件所需的最低因子 VIII 活性(“水平”)和理想因子 VIII 活性的意见。

方法

基于 2017 年国家血友病基金会 PA 描述,临床专家估计了在避免出血的情况下可接受的最低因子水平和理想因子水平。使用一种构建概率分布的方法来量化估计值的不确定性,以代表专家意见。

结果

无论是否存在关节疾病,较高风险的 PA 所需的最小和理想因子水平以及专家对其估计的不确定性(即最低和最高估计值之间的范围)均会增加。对于没有关节疾病的人,从低风险到高风险的最小因子水平范围从 4%到 48%,对于有关节疾病的人,最小因子水平范围从 7%到 47%。对于理想因子水平,相应的数字分别为 9%-52%和 12%-64%。

结论

为了支持以患者为中心的结果,专家意见表明,0.01 IU/mL(1%)的最低水平不足以满足临床需要。预计引入更有针对性的方法来满足越来越活跃的患者的需求,除了最近的治疗进展外,还将使患者进一步受益。

相似文献

1
Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise.了解血友病患者参与体育活动的最低和理想因子水平:一项专家 elicitation 研究。
Haemophilia. 2020 Jul;26(4):711-717. doi: 10.1111/hae.13985. Epub 2020 Apr 8.
2
Outcome in moderate haemophilia.中度血友病的结局。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s330-6. doi: 10.2450/2012.0091-12. Epub 2012 Nov 20.
3
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.血友病预防性治疗中剂量、凝血因子水平及出血与关节状态关系的6年随访
Haemophilia. 2004 Nov;10(6):689-97. doi: 10.1111/j.1365-2516.2004.01036.x.
4
Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.在重度血友病中提前停止预防治疗会导致关节状况恶化,尽管出血率较低。
Thromb Haemost. 2016 May 2;115(5):931-8. doi: 10.1160/TH15-08-0637. Epub 2016 Jan 21.
5
Physical activity levels in men with Haemophilia-A single centre UK survey.血友病 A 男性患者的身体活动水平:一项英国单中心调查。
Haemophilia. 2020 Jul;26(4):718-725. doi: 10.1111/hae.14009. Epub 2020 May 4.
6
When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study.儿童何时被诊断为患有重度血友病,以及他们何时开始出血?一项为期10年的单中心前瞻性队列研究。
Eur J Pediatr. 1999 Dec;158 Suppl 3:S166-70. doi: 10.1007/pl00014347.
7
Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).重度或中度重度血友病青少年及年轻成人的凝血因子 VIII/IX 治疗方案选择。一项法国全国性观察性研究(ORTHem 15 - 25)
Thromb Res. 2017 Mar;151:17-22. doi: 10.1016/j.thromres.2016.12.023. Epub 2016 Dec 28.
8
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.建模预测接受三级预防治疗的重度 A 型血友病患者零出血相关的因子 VIII 水平。
Thromb Haemost. 2020 May;120(5):728-736. doi: 10.1055/s-0040-1709519. Epub 2020 May 5.
9
Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis.重度血友病患者的运动参与情况:接受预防治疗儿童的出血及关节情况
Pediatrics. 2009 Nov;124(5):1267-72. doi: 10.1542/peds.2009-0072. Epub 2009 Oct 12.
10
Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.血友病患者的身体活动以及重组因子VIII Fc融合蛋白和重组因子IX Fc融合蛋白治疗活跃期患者的经验:文献综述与病例报告
Blood Coagul Fibrinolysis. 2016 Oct;27(7):737-744. doi: 10.1097/MBC.0000000000000565.

引用本文的文献

1
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab.翼(TSUBASA)研究:评估接受艾美赛珠单抗治疗的无因子VIII抑制剂的A型血友病患者身体活动与出血事件之间的关联。
Haemophilia. 2025 Jul;31(4):703-712. doi: 10.1111/hae.70070. Epub 2025 Jun 18.
2
Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.重组因子IX-白蛋白融合蛋白(rIX-FP)预防性治疗B型血友病患者的六年真实世界应用:一项单中心回顾性-前瞻性研究。
J Clin Med. 2024 Mar 6;13(5):1518. doi: 10.3390/jcm13051518.
3
The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies.
血友病研究中特定出血类型年出血率的必要性。
JMIR Public Health Surveill. 2024 Mar 13;10:e51372. doi: 10.2196/51372.
4
Considerations for shared decision management in previously untreated patients with hemophilia A or B.对既往未经治疗的甲型或乙型血友病患者进行共同决策管理的考量
Ther Adv Hematol. 2023 Apr 17;14:20406207231165857. doi: 10.1177/20406207231165857. eCollection 2023.
5
IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.IDEAL 研究:在意大利,对重组凝血因子 IX 白蛋白融合蛋白(rIX-FP)在乙型血友病患者中的使用模式和临床结局的真实世界评估。
Haemophilia. 2023 Jan;29(1):135-144. doi: 10.1111/hae.14689. Epub 2022 Nov 24.
6
Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A.探索甲型血友病患儿在不同体力活动水平下的最低所需FVIII水平。
Front Pediatr. 2022 Nov 1;10:1045070. doi: 10.3389/fped.2022.1045070. eCollection 2022.
7
Improving Care of Older Patients with Hemophilia During COVID-19 Pandemic, Reducing the Risk of Venous Thrombosis with Home Exercises.在新冠疫情期间改善老年血友病患者的护理,通过居家锻炼降低静脉血栓形成风险。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087223. doi: 10.1177/10760296221087223.
8
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.重度甲型血友病无抑制物患者的当前治疗选择与管理:小型德尔菲共识
J Clin Med. 2022 Feb 2;11(3):801. doi: 10.3390/jcm11030801.
9
How do we optimally utilize factor concentrates in persons with hemophilia?我们应如何优化利用因子浓缩物治疗血友病患者?
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):206-214. doi: 10.1182/hematology.2021000310.
10
The Role of Physiotherapy in the New Treatment Landscape for Haemophilia.物理治疗在血友病新治疗格局中的作用
J Clin Med. 2021 Jun 26;10(13):2822. doi: 10.3390/jcm10132822.